Publications by Prof. van Dongen and colleagues

First or last authorship: journals

1. Van Dongen GAMS, Van de Zande L, Schamhart DHJ, Van Wijk R; Comparative studies on the heat induced thermotolerance of protein synthesis and cell division of synchronized mouse neuroblastoma cells. Int J Radiat Biol 46: 759-769 (1984).

2. Van Dongen GAMS, Zoutewelle G, Van Rijn J, Van Wijk R; Cell killing and sensitisation to heat shock by hypothermic incubation of asynchronous and synchronized mouse neuroblastoma cells. Cancer Res 45: 4132-4137 (1985).

3. Van Dongen GAMS and Van Wijk R; Effect of serum on heat response of synchronized mouse neuroblastoma cells: protection of cell cycle progression, protein synthesis and survival. Int J Radiat Biol 50: 77-90 (1986).

4. Van Dongen GAMS, Geilenkirchen WLM, Van Rijn J, Van Wijk R; Increase of thermoresistance after growth stimulation of Reuber 35H cells: alterations of nuclear characteristics, non-histone chromosomal protein phosphorylation and basal heat shock protein synthesis. Exp Cell Res 156: 427-441 (1986).

5. Van Dongen GAMS and Van Wijk R; Evidence for a role of heat shock proteins in proliferation after heat treatment of synchronized mouse neuroblastoma cells. Radiat Res 113, 252-267 (1988).

6. Van Dongen GAMS, Braakhuis BJM, Bagnay M, Leyva A, Snow GB; Activity of differentiation-inducing agents and conventional drugs in head and neck cancer xenografts. Acta Oto-Laryngologica (Stockh). 105: 488-492 (1988).

7. Van Dongen GAMS, Braakhuis BJM, Leyva A, Hendriks HR, Kipp BBA, Bagnay M, Snow GB. Antitumor and differentiation-inducing activity of N,N-dimethylformamide (DMF) in head and neck cancer xenografts. Int J Cancer 43: 285-292 (1989).

8. Schrijvers AHGJ, Gerretsen M, Fritz J, Van Walsum M, Quak JJ, Snow GB, Van Dongen GAMS. Evidence for a role of the monoclonal antibody 48E defined antigen in cell-cell adhesion in squamous epithelia and head and neck squamous cell carcinomas. Exp Cell Res 196: 264-269 (1991).

9. Quak JJ, and van Dongen GAMS. Detectie van hoofd/hals tumoren met radioactief gelabelde monoclonale antilichamen. Tijdschrift Kanker 15: 48-49 (1991).

10. Gerretsen M, Quak JJ, Suh JS, Van Walsum M, Meijer CJLM, Snow GB, Van Dongen GAMS. Superior localisation and imaging of radiolabelled monoclonal antibody 48E (Fab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody 48E IgG. Br J Cancer 63: 37-44 (1991).

11. Quak JJ, Schrijvers AHGJ, Brakkee JGP, Davis HD, Scheper RJ, Balm AJM, Meijer CJLM, Snow GB, Van Dongen GAMS. Expression and characterization of two differentiation antigens in stratified squamous epithelia and carcinomas. Int J Cancer 50: 507-513 (1992).

12. Gerretsen M, Schrijvers AHGJ, Van Walsum M, Braakhuis BJM, Snow GB, Van Dongen GAMS. Radioimmunotherapy of head and neck squamous cell carcinoma with 131I-labeled monoclonal antibody 48E. Br J Cancer 66: 496-502 (1992).

13. Schrijvers AHGJ, Quak JJ, Gerretsen M, Van Walsum M, Braakhuis BJM, Snow GB, Van Dongen GAMS. Perspectives for radioimmunoscintigraphy of head and neck squamous cell carcinoma with monoclonal antibody 984K. Cancer Immunol Immunother 34: 252-258 (1992).

14.*** Van Dongen GAMS, Leverstein H, Roos JC, Quak JJ, Van den Brekel M, Van Lingen A, Martens HJM, Castelijns J, Visser GWM, Meijer CJLM, Teule JJ, Snow GB. Radioimmunoscintigraphy of head and neck tumors using 99mTc-labeled monoclonal antibody 48E F(ab')2. Cancer Res 52: 2569-2574 (1992).

15. Schrijvers AHGJ, Quak JJ, Uyterlinde AM, Van Walsum M, Meijer CJLM, Snow GB, Van Dongen GAMS. MAb 36U, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 53: 3524-3529 (1993).

16. Visser G, Gerretsen M, Herscheid J, Snow GB, Van Dongen GAMS. Labeling of monoclonal antibodies with 186Re using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 34: 1953-1963 (1993).

17. Gerretsen M, Visser GWM, Van Walsum M, Meijer CJLM, Snow GB, Van Dongen GAMS. 186Re-labeled monoclonal antibody 48E IgG mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 53: 3524-3529 (1993).

18. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Clinical screening of monoclonal antibodies 323/A3 (931K), cSF-25 (984K), and 928K for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nuclear Medicine Communications 15: 613-627 (1994).

19. Brakenhoff RH, Knippels EMC, Van Dongen GAMS. Optimization and simplification of expression cloning in eukaryotic vector/host systems. Anal Biochem 216: 460-463 (1994).

20.*** De Bree R, Roos JC, Quak JJ, Den Hollander W, Van den Brekel MWM, Van de Wal JE, Snow GB, Van Dongen GAMS. Clinical imaging of head and neck cancer with 99mTc-labeled monoclonal antibody 48E IgG or F(ab')2. J Nucl Med 35: 775-783 (1994).

21. Gerretsen M, Quak JJ, Brakenhoff RH, Snow GB, Van Dongen GAMS. The feasibility of radioimmunotherapy in head and neck cancer. Eur J Cancer Part B; Oral Oncol B: 82-87 (1994).

22. Gerretsen M, Visser GWM, Brakenhoff RH, van Walsum M, Snow GB, Van Dongen GAMS. Complete ablation of small head and neck cancer xenografts with 186Re-labeled MAb 48E IgG. Cell Biophys 24: 135-142 (1994).

23. Quak JJ, and Van Dongen GAMS. Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors. Eur Arch ORL 251: 1-5 (1994).

24. Van Dongen GAMS, Brakenhoff RH, De Bree R, Gerretsen M, Quak JJ, Snow GB. Progress in radioimmunotherapy of head and neck cancer. Oncology Reports 1: 259-264 (1994).

25.*** De Bree R, Roos JJ, Quak JJ, Den Hollander W, Wilhelm AJ, van Lingen A, Snow GB, Van Dongen GAMS. Biodistribution of radiolabeled monoclonal antibody 48E IgG and F(ab')2 in patients with head and neck cancer. Clin Cancer Res 1: 277-286 (1995).

26.*** De Bree R, Roos JJ, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Radioimmunoscintigraphy with 99mTc-labeled monoclonal antibody 36U and its biodistribution in patients with head and neck cancer. Clin Cancer Res 1: 591-598 (1995).

27. Brakenhoff RH, Van Gog FB, Looney JE, Van Walsum M, Snow GB, Van Dongen GAMS. Construction and characterization of the chimeric monoclonal antibody 48E for therapy of head and neck cancer. Cancer Immunol Immunother 40: 351-358 (1995).

28. Brakenhoff RH, Gerretsen M, Knippels EMC, Van Dijk M, Van Essen H, Olde-Weghuis D, Sinke R, Snow GB, Van Dongen GAMS. The human 48E antigen, highly homologous to the murine Ly- antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 129: 191-200 (1995).

29. Van Gog FB, Visser GWM, Klok R, Van der Schors R, Snow GB, Van Dongen GAMS. Monoclonal antibodies labeled with a high dose of rhenium-186 using the MAG3 chelate for clinical application: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med 37: 352-362 (1996).

30. Van Dongen GAMS, Brakenhoff RH, Ten Brink C, Van Gog F, De Bree R, Quak JJ, Snow GB. Sqaumous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. Anticancer Res 16: 2409-2414 (1996).

31.*** De Bree R, Roos JC, Quak JJ, Van Kamp GJ, Den Hollander W, Snow GB, Van Dongen GAMS. Selection of monoclonal antibody 48E IgG or 36U for adjuvant therapy in head and neck cancer patients. Brit J Cancer 75: 1049-1060 (1997).

32. Van Gog FB, Brakenhoff RH, Snow GB, Van Dongen GAMS. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice. Cancer Immunol Immunother 44: 103-111 (1997).

33. Van Gog FB, Visser GWM, Stroomer JWG, Snow GB, Van Dongen GAMS. High dose 186Re-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 80, 2360-2370 (1997).

34. Van Dongen GAMS, and Snow GB. Prospects for future studies in head and neck cancer. Eur J Surg Oncol 23: 492-494 (1997).

35. Van Gog FB, Brakenhoff RH, Stigter-Van Walsum M, Snow GB, Van Dongen GAMS. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 77: 13-18 (1998).

36. Van Gog FB, Visser GWM, Gowrising RWA, Snow GB, Van Dongen GAMS. Synthesis and evaluation of 99mTc/99Tc-MAG3-biotin conjugates for antibody pretargeting strategies. Nucl Med Biol 25: 611-619 (1998).

37.*** De Bree R, Kuik DJ, Quak JJ, Roos JC, Van den Brekel MWM, Castelijns JA, Van Wagtendonk FW, Greuter H, Snow GB, Van Dongen GAMS. The impact of tumour volume and other characteristics on uptake of radiolabeled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur J Nucl Med 25: 1562-1565 (1998).

38. Vrouenraets MB, Visser GWM, Stewart FA, Stigter M. Oppelaar H, Postmus PE, Snow GB, Van Dongen GAMS. Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res 59: 1505-1513 (1999).

39. Brakenhoff RH, Stroomer JGW, Ten Brink C, De Bree R, Weima SM, Snow GB, Van Dongen GAMS. Sensitive detection of squamous cells in bone marrow and blood in head and neck cancer patients by 48E reverse transcriptase polymerase chain reaction. Clin Cancer Res 5, 725-732 (1999).

40.*** Stroomer JWG, Roos JC, Sproll M, Quak JJ, Heider K-H, Wilhelm AJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GA, Van Dongen GAMS. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1, in head and neck cancer patients. Clin Cancer Res 6: 3046-3055 (2000).

41.*** Colnot DR, Quak JJ, Roos JC, Van Lingen A, Wilhelm AJ, Van Kamp GJ, Huijgens PC, Snow GB, Van Dongen GAMS. Phase I therapy study of Rhenium-186-labeled chimeric monoclonal antibody 36U in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41: 1999-2010 (2000).

42. Vrouenraets MB, Visser GWM, Loup C, Meunier B, Stigter M, Oppelaar H, Stewart FA, Snow GB, Van Dongen GAMS. Targeting of a hydrophylic photosensitizer by use of internalizing monoclonal antibodies: a new possibility for use in photodynamic therapy. Int J Cancer 88: 108-114 (2000).

43.*** Colnot DR, Quak JJ, Roos JC, De Bree R, Wilhelm AJ, Snow GB, Van Dongen GAMS. Radioimmunotherapy in patients with head and neck squamous cell carcinoma – initial experience. Head and Neck 23, 559-565 (2000).

44.*** Colnot DR, Wilhelm AJ, Cloos J, Roos JC, de Bree R, Quak JJ, Snow GB, Van Dongen GAMS. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb 36U radioimmunotherapy. J Nucl Med 42, 1364-1367 (2001).

45. Vrouenraets MB, Visser GWM, Stigter M, Oppelaar H, Snow GB, Van Dongen GAMS. Targeting of aluminium phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res 61: 1970-1975 (2001).

46. Vrouenraets MB, Visser GWM, Stigter M, Oppelaar H, Snow GB, Van Dongen GAMS. Comparison of aluminium (III) phthalocyanine tetrasulphonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro. Int J Cancer 98, 793-798 (2002).

47. Verel I, Heider K-H, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow, GB, Adolf GR, Van Dongen GAMS. Tumour targeting properties of monoclonal antibodies with different affinity for the target antigen 44CDv6 in nude mice bearing head and neck cancer xenografts. Int J Cancer 99, 396-402 (2002).

48.*** Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, De Bree R, Börjesson PKE, Huijgens PC, Snow GB, Van Dongen GAMS. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Re-labeled chimeric monoclonal antibody 36U radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 8, 3401-3406 (2002).

49. Verel I, Visser GWM, Boerman OC, Van Eerd JEM, Finn R, Boellaard R, Vosjan M, Stigter-van Walsum M, Snow GB, Van Dongen GAMS. The long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Biopharm 18, 655-661 (2003).

50. Vrouenraets MB, Visser GWM, Snow GB, Van Dongen GAMS. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res 23, 505-522 (2003).

51. Verel I, Visser GWM, Boellaard R, Stigter-Van Walsum M, Snow GB, Van Dongen GAMS. Zirconium-89 immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibody. J Nucl Med 44, 1271-1281 (2003).

52.*** Börjesson PKE, Postema EJ, Roos JC, Colnot DR, Marres HAM, Van Schie MH, Stehle G, De Bree R, Snow GB, Van Dongen GAMS. Phase I therapy with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9, 3961s-3972s (2003).

53.*** Colnot DR, Roos JC, De Bree R, Wilhelm AJ, Stehle G, Snow GB, Van Dongen GAMS. Safety, biodistribution, and immunogenicity of the intermediate affinity 99mTc-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with squamous cell carcinoma of the head and neck. J Immunol Immunother 52, 576-582 (2003).

54. Verel I, Visser GWM, Boellaard R, Boerman OC, Van Eerd J, Snow GB, Lammertsma AA, Van Dongen GAMS. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J. Nucl Med 44, 1663-1670 (2003).

55. Van Dongen GAMS, Visser GWM, Vrouenraets MB. Photosensitizer immunoconjugates. Adv Drug Deliv Rev 13, 31-52 (2003).

56. Börjesson PKE, Postema EJ, De Bree R, Roos JC, Leemans CR, Kairemo KJA, Van Dongen GAMS. Radioimmunodetection and radioimmunotherapy of head and neck cancer. Oral Oncol 40, 761-772 (2003).

57. Verel I, Visser GWM, Vosjan MJWD, Finn R, Boellaard R, Van Dongen GAMS. High quality 124I-labeled monoclonal antibodies for use as PET-scouting agent prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging 31, 1645-1652 (2004).

58. Verel I, Visser GWM, Van Dongen GAMS. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 46, tS-yS (2005).

59. Perk LR, Visser GWM, Vosjan MJWD, Stigter-van Walsum M, Tijink BM, Leemans CR, Van Dongen GAMS. Evaluation of 89Zr as a PET surrogate radioisotope for scouting the biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor bearing nude mice, after coupling to the internalizing antibody cetuximab. J Nucl Med 46, 1998-1906 (2005).

60.*** Börjesson PKE, Jauw YWS, Boellaard R, De Bree R, Comans EFI, Roos JC, Castelijns JA, Vosjan MJDW, Kummer A. Leemans CR, Lammertsma AA, Van Dongen GAMS. Performance of immuno-PET with zirconium-89-labeled chimeric monoclonal antibody 36U in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res, 12, 2133-2140 (2006).

61. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-Van Walsum M, Zardi L, Van Dongen GAMS. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody 19L-SIP for selective targeting of tumor vasculature. J Nucl Med 47, 1127-1135 (2006).

62.*** Perk LR, Visser OJ, Stigter-Van Walsum M, Vosjan MJWD, Visser GWM, Zijlstra JM, Huijgens PC, Van Dongen GAMS. Preparation and evaluation of 89Zr-Zevalin for monitoring 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 33, 1337-1345 (2006).

63.*** Tijink BM, Buter J, De Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, Van Dongen GAMS. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with advanced squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12, 6064-6072 (2006).

64. Van Dongen GAMS, Visser GWM, Lub-de Hooge MN, De Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. The Oncologist 12, 1379-1389 (2007).

65. Perk LR, Visser GWM, Budde M, Vosjan MJWD, Jurek P, Kiefer GE, Van Dongen GAMS. Facile radiolabeling of monoclonal antibodies and other proteins with zirconium-89 or gallium-68 for PET using p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2008. DOI 10.1038/nprot.2008.22.

66. Perk LR, Stigter-van Walsum M, Visser GWM, Kloet RW, Vosjan MJWD, Leemans CR, Giaccone G, Albano R, Comoglio PM, Van Dongen GAMS. Quantitative PET imaging of Met expressing human cancer xenografts with 89Zr-labelled monoclonal antibody 30DN. Eur J Nucl Med Mol Imaging 10, 1857-1867 (2008).

67. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, De Haard HJ, Leemans CR, Van Dongen GAMS. Improved tumor targeting of anti-EGFR nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 7, 2288-2297 (2008).

68. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser, GWM, Kloet RW, MSc2, Dinkelborg LM, Leemans CR, Neri D, Van Dongen GAMS. 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging, 36, 1235-1244 (2009).

69. Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, Van Dongen GAMS. p-Isothiocyanatobenzyl-desferrioxamine: a new bifucntional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 37, 250-259 (2010).

70. Heuveling D, De Bree R, Van Dongen GAMS. The role of PET in head and neck cancer: more than 18FDG alone. Otorinolaryngologica, 59, 141-155 (2009).

71. Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, Van Dongen GAMS. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nature Prot 5, 739-743 (2010).

72. Van Dongen GAMS and Vosjan MJDW. Immuno-PET: shedding light on clinical antibody development. Cancer Biother Radiopharm 25, 375-385 (2010).

73. Vosjan MJDW, Perk LR, Roovers RC, Visser GWM, Stigter-Van Walsum M, Van Bergen en Henegouwen P, Van Dongen GAMS. Facile labeling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifucntional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging, 38, 753-763 (2011).

74. Heuveling D, De Bree R, Van Dongen GAMS. The potential role of non-FDG-PET in the management of head and neck cancer. Oral Oncol 47, 2-7 (2011).

75. Heuveling DA, Visser GWM, Baclayon M, Roos WH, Wuitte GJL, Hoekstra OS, Leemans CR, De Bree R, Van Dongen GAMS. 89Zr-nanocolloid albumin-based PET-CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results. J Nucl Med, 52, 1580-1584 (2011).

76. Vugts DJ, Vervoort A, Stigter-Van walsum M, Visser GWM, Robillard MS, Versteegen RM, Vulders RCM, Herscheid JDM, Van Dongen GAMS. Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeting imagng and therapy approach. Bioconjate Chem 22, 2072-2081 (2011).

77. Becker R, Van Dongen GAMS. EATRIS, a vision for translational research in Europe. J Cardiovasc Transl Res 4, 231-237 (2011).

78. Cohen R, Stammes MA, De Roos IHC, Stigter-van Walsum, Visser GWM, Van Dongen GAMS. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. Eur J Nucl Med Mol Imaging Res 1, 31 (2011.)

79. Vugts DJ and Van Dongen GAMS. 89Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discovery Today Technology 8, 53e-e61 (2011).

80. Van Dongen GAMS, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumor Biol 33, 607-615 (2012).

81. Heuveling DA, Visser GWM, De Groot M, De Boer JF, Baclayon M, Roos WH, Wuite GJL, Leemans R, De Bree R, Van Dongen GAMS. Nanocolloidal albumin-IRDye800CW: a near-infrared fluorecent tracer with optimal retention in the sentinel lymph node. Eur J Nucl Med Mol Imaging 39, 1161-1168 (2012).

82. Vosjan MJWD, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, Van Dongen GAMS. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Cancer Mol Ther 11, 1017-1025 (2012).

83. Slobbe P, Poot AJ, Windhorst AB, Van Dongen GAMS. PET imaging with small-molecule tyrosine kinase inhibitors. Drug Discovery Today 17, 1175-1187 (2012).

84. Van Dongen GAMS, Ussi A, De Man F, Migliaccio G. EATRIS, a European initiative to boost Translational biomedical research. Curr Mol Med, in press (2013).

85. Heuveling DA, De Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra O, Leemans CR, Neri D, Van Dongen GAMS. Phase 0 microdosing PET study using the human mini antibody 16FSIP in head and neck cancer patients. J Nucl Med, in press (2013).

Co-authorship: journals


86. Streumer-Svobodova Z, Wiegant FAC, Van Dongen GAMS, van Wijk R; Variations in some molecular events during early phases of the Reuber 35H hepatoma cell cycle. III: Role of protein synthesis in the initiation of DNA synthesis and the mechanism of stimulation of protein synthesis by serum. Biochimie 64: 411-418 (1982).

87. Dingemans KP, Pels E, Van Dongen GAMS, Den Otter W; Destruction of murine lymphoma cells by allogenic peritoneal macrophages in vitro: Influence of antiserum. J Natl Cancer Inst 70: 181-192 (1983).

88. Van Bergen en Henegouwen PMP, Jordi WJRM, Van Dongen GAMS, Ramaekers FCM, Amesz H, Linnemans WAM; Studies on the possible relationship between alterations in the cytoskeleton and induction of heat shock protein synthesis in mammalian cells. Int J Hyperthermia 1: 69-83 (1985).

89. Wiegant FAC, Van Bergen en Henegouwen PJP, Van Dongen GAMS, and Linnemans WAM; Stress-induced thermotolerance of the cytoskeleton of mouse neuroblastoma N2A cells and the rat Reuber 35H hepatoma cells. Cancer Res 47: 1674-1680 (1987).

90. Braakhuis BJM, Van Dongen GAMS, Van Walsum M, Leyva A, Snow GB; Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human head and neck cancer xenografts. Invest. New Drugs 6: 299-304 (1988).

91. Braakhuis BJM, Laarman DAW, Nauta JJ, Van Dongen GAMS, Van Walsum M, Snow GB; Transplantability of head and neck squamous cell carcinoma in athymic nude mice. Arch. Otolaryngol./Head & Neck Surg. 115: 1076-1078 (1989).

92. Braakhuis BJM, Van Dongen GAMS, Bagnay M, van Walsum M, Snow GB. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice. Head & Neck 11: 511-515 (1989).

93. Brown DH, Braakhuis BJM, Van Dongen GAMS, van Walsum M, Bagnay M, Snow GB. Activity of the folate analog 10-Ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts. Anticancer Res 9: 1549-1552 (1990).

94. Quak JJ, Van Dongen GAMS, Balm AJM, Brakkee JPG, Scheper RJ, Snow GB, Meijer CJLM. A 22-kDa surface antigen detected by monoclonal antibody 48E is exclusively expressed in stratified squamous and transitional epithelia. Am J Pathol 136: 191-197 (1990).

95. Quak JJ, Van Dongen GAMS, Gerretsen M, Hayashida D, Balm AJM, Brakkee JPG, Snow GB, Meijer CJLM. Production of monoclonal antibody (931K) to a squamous cell carcinoma antigen identified as the 17-1A antigen. Hybridoma 9: 377-387 (1990).

96. Quak JJ, Van Dongen GAMS, Balm AJM, Brakkee JPG, Scheper RJ, De Jonge L, Meijer CJLM, Snow GB. Identification of a 43 kDa nuclear antigen associated with proliferation by monoclonal antibody 112K. Int J Cancer 46: 50-55 (1990).

97. Brown DH, Braakhuis BJM, Van Dongen GAMS, Snow GB; Comparative study of the sensitivity of head and neck cell lines to methotrexate and the analog 10-ethyl, 10-deaza-aminopterin (10-EdAM). Otolaryngol/Head Neck Surg 102: 20-25 (1990).

98. Braakhuis BJM, Van Dongen GAMS, Peters GJ, Van Walsum M, Snow GB. Antitumor activity of Brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts. Cancer Letters 49: 133-137 (1990).

99. Braakhuis BJM, Van Dongen GAMS, Vermorken J, Snow GB. Preclinical in vivo activity of 2',2'-difluorodeoxy-cytidine (Gemcitabine) against human head and neck carcinomas. Cancer Res 51: 211-214 (1991).

100. Quak JJ, Gerretsen M, Schrijvers A, Meijer CJLM, Van Dongen GAMS, Snow GB. Detection of squamous cell carcinoma xenografts in nude mice by radiolabeled monoclonal antibody 48E. Arch Otolaryngol/Head Neck Surg 117: 1287-1291 (1991).

101. Zatterstrom UK, Braakhuis BJ, Wennerberg J, Van Dongen GAMS, Attewell R, Nauta JJ, Laarman DA, Ask A. Growth of xenografted squamous cell carcinoma of the head and neck-possible correlation with patient survival. APMIS 100: 976-980 (1992).

102. Copper MP, Braakhuis BJ, De Vries N, Van Dongen GAMS, Nauta JJ, Snow GB. A panel of biomarkers of carcinogenesis of the upper digestive tract as potential intermediate endpoints in chemoprevention trials. Cancer 71: 825-830 (1993).

103. Quak JJ, Gerretsen M, De Bree R, Brakenhoff R, Van Dongen GAMS, Snow GB. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours. Anticancer Res 13, 2533-2540 (1993).

104. Gripp FM, Quak JJ, Leverstein H, Schrijvers A, Gerretsen M, Brakenhoff R, Van Dongen GAMS, Snow GB, Rapoport A. Monoclonal antibodies for diagnosis and therapy of squamous cell carcinoma of the head and neck. Rev Paul Med 112: 613-627 (1994).

105. Sung M-W, Yasamura S, Johnson JT, Van Dongen GAMS, Whiteside TL. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous cell carcinoma of the head and neck. Int J Cancer 61: 864-872 (1995).

106. Sung MW, Nagashima S, Johnson JT, Van Dongen GAMS, Whiteside TL. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity (ADCC) against monolayers of human squamous cell carcinoma of the head and neck (SCCHN) targets. Cellular Immunol 171: 20-29 (1996).

107. Sung M-W, Johnson JT, Van Dongen GAMS, Whiteside TL. Protective effect of interferon- on squamous cell carcinoma of the head and neck targets in antibody dependent cellular cytotoxicity mediated by human NK cells. Int J Cancer 66: 393-399 (1996).

108. Van Hal N, Van Dongen GAMS, Rood-Knippels EMC, Van der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody 36U, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a 44CD isoform. Int J Cancer 68: 520-527 (1996).

109. Kievit E, Van Gog FB, Schlüper HMM, Van Dongen GAMS, Pinedo HM, Boven E. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts. Int J Radiat Oncol Biol Phys 38, 813-823 (1997).

110. Van Hal NLW, Van Dongen GAMS, Ten Brink CBD, Herron JN, Snow GB, Brakenhoff RH. Sequence variation in the monoclonal antibody 36U defined 44CDv6 epitope. Cancer Immunol Immunother 45, 88-92 (1997).

111. Kievit E, Van Gog FB, Schlüper HMM, Van Dongen GAMS, Pinedo HM, Boven E. 186Re-labeled mouse and chimeric monoclonal antibody 323/A3: a comparison of the efficacy in experimental ovarian cancer. Nucl Med Biol 25: 27-35 (1998).

112. Van Hal NLW, Van Dongen GAMS, Stigter-Van Walsum M, Snow GB, Brakenhoff GB. Characterization of 44CDv6 isoforms in head and neck squamous cell carcinoma. Int J Cancer 82: 837-845 (1999).

113. Van Hal NJW, Van Dongen GAMS, Ten Brink CBM, Heider K-H, Rech-Weichselbraun I, Snow GB, Brakenhoff RH. Evaluation of soluble 44CDv6 as potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res 5: 3534-3541 (1999).

114. Eshel R, Zanin A, Sagi-Assif O, Meshel T, Smorodinsky NI, Dwir O, Alon R, Brakenhoff RH, Van Dongen GAMS, Witz IP. The GPI-linked Ly- antigen 48E regulates expression levels of the FX-enzyme and of E-selectin ligands on head and neck squamous carcinoma cells. J Biol Chem 275: 12833-12840 (2000).

115. Visser GWM, Klok RP, Klein-Gebbink JW, Ter Linde T, Van Dongen GAMS, Molthoff CF. Optimal quality Iodine-131-monoclonal antibodies upon high dose labeling in a large reaction volume and temporarily coating the antibody with iodogen. J Nucl Med 42: 509-519 (2001).

116. Geldof AA, Versteegh LRT, Van Mourik JC, Rooimans MA, Arwert F, Hermsen MA, Schadee-Eestermans IL, Van Dongen GAMS, van der Valk P, van der Clement EHP, Lips P, Teule GJ. Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (2609TT). Thyroid 11, 909-917 (2001).

117. Eshel R, Zanin A, sagi-Assif O, Meshel T, Smorodinsky NI, Dwir O, Alon R, Brakenhoff RH, Van Dongen GAMS, Witz IP. Human Ly- antigen 48E (Ly-D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells. Int J Cancer 98, 803-810 (2002).

118. De Nooij-Van Dalen, Van Dongen GAMS, Smeets SJ, Stigter-Van Walsum M, Snow GB, Brakenhoff RH. Characterization of the human Ly- antigens, the newly annotated member Ly-K included, as molecular marker for head and neck squamous cell carcinoma. Int J Cancer 103, 768-774 (2003).

119.*** De Bree R, Roos JC, Verel I, Van Dongen GAMS, Snow GB. Radioimmunodiagnosis of lymph node metastases in head and neck cancer. Oral Dis 9, 241-248 (2003).

120. Nestor M, Persson M, Cheng J, Tolmachev V, Van Dongen GAMS, Anniko M, Kairemo K. Biodistribution of the chimeric monoclonal antibody 36U radioiodinated with a closo-dodecaborate containing linker. Comparison with other radioiodination methods. Bioconjugate Chem 14, 805-810 (2003).

121.*** Postema EJ, Raemaekers JMM, Oyen WJG, Boerman OC, Mandigers CMPW, Goldenberg DM, Van Dongen GAMS, Corstens FHM. Final results of a phase I radioimmunotherapy trial using 186Re-Epratuzumab for the treatment of patients with non-Hodgkin‘s lymphoma. Clin Cancer Res 9, 995s-